{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:38:33Z","timestamp":1777045113698,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ygyno.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:56:34Z","timestamp":1755881794000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy"],"prefix":"10.1016","volume":"201","author":[{"given":"Daniel R.","family":"Cherry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Kolev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen P.","family":"Zeligs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjeet","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2025.08.002_bb0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990\u20132019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.002_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"9717","key":"10.1016\/j.ygyno.2025.08.002_bb0020","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/gyno.1994.1208","article-title":"Uterine papillary serous carcinoma: patterns of metastatic spread","volume":"54","author":"Goff","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.002_bb0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00000478-199206000-00008","article-title":"Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features","volume":"16","author":"Sherman","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2025.08.002_bb0040","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine Corpus Cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of Nonendometrioid cancers","volume":"37","author":"Clarke","year":"2019","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.002_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2017.07.145","article-title":"Impact of age at diagnosis on racial disparities in endometrial cancer patients","volume":"149","author":"Tarney","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2013.05.020","article-title":"Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States","volume":"130","author":"Long","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.002_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2023.09.009","article-title":"TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes","volume":"178","author":"Whelan","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.002_bb0060","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1158\/2159-8290.CD-23-0546","article-title":"Molecular characterization of endometrial carcinomas in Black and White patients reveals disparate drivers with therapeutic implications","volume":"13","author":"Weigelt","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.002_bb0070","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.002_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/IGC.0000000000000569","article-title":"Uterine papillary serous carcinoma: a single-institution review of 62 cases","volume":"26","author":"Black","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.08.002_bb0080","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.2147\/CMAR.S179566","article-title":"Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases","volume":"10","author":"Wang","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy","volume":"91","author":"Huh","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.002_bb0095","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ije\/dyz032","article-title":"Accounting for missing data in statistical analyses: multiple imputation is not always the answer","volume":"48","author":"Hughes","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2025.08.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.002_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.002_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"7","key":"10.1016\/j.ygyno.2025.08.002_bb0115","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/cancers16071346","article-title":"Risk-tailoring radiotherapy for endometrial Cancer: a narrative review","volume":"16","author":"Hsieh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2025.08.002_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2024.04.016","article-title":"Prognostic performance of the 2023 FIGO staging schema for endometrial cancer","volume":"187","author":"Matsuo","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.002_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2024.06.024","article-title":"Uterine cancer restaging according to the updated 2023 FIGO guidelines does not uniformly affect prognosis: an institutional retrospective cohort study","volume":"189","author":"Senguttuvan","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.002_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2025.08.002_bb0140","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.002_bb0145","series-title":"Testing the Addition of Trastuzumab or Trastuzumab\/Pertuzumab to the Usual Chemotherapy for HER2 Positive Uterine Serous or Carcinosarcoma (NRG-GY026)","year":"2025"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.002_bb0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/AOG.0000000000004676","article-title":"The changing landscape of gynecologic cancer mortality in the United States","volume":"139","author":"Giaquinto","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.23717","article-title":"Racial disparities in recurrence among patients with early stage endometrial cancer: is recurrence increased in Black patients on estrogen replacement therapy?: a gynecologic oncology group study","volume":"113","author":"Maxwell","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.002_bb0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2021.07.022","article-title":"Racial disparities in survival among women with endometrial cancer in an equal access system","volume":"163","author":"Park","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.002_bb0165","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2022.0009","article-title":"Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype","volume":"8","author":"Clarke","year":"2022","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:38:54Z","timestamp":1762562334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825009503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S0090825825009503"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}